Akari Therapeutics (AKTX) Interim CFO Farag Kameel Receives RSU Award

What Happened

• Farag Kameel D., Interim Chief Financial Officer of Akari Therapeutics plc (AKTX), was granted 1,728 American Depositary Shares (reported as RSU awards) on 2026-08-17. The grant is reported at $7.52 per ADS for a total reported value of $12,995. This was an award/grant (code A), not an open-market purchase or sale.

Key Details

• Transaction date: 2026-08-17; Form 4 filed: 2026-08-19 (timely filing).
• Awarded: 1,728 ADS; reported price: $7.52; reported total value: $12,995.
• Shares owned after the transaction: not specified in the provided filing summary.
• Footnote: These ADS are restricted stock units (RSUs). Each RSU represents the right to receive 80,000 ordinary shares (par value $0.000000005). The RSUs vest in full on September 15, 2026.
• Transaction code: A = Award/Grant.

Context

• This was a grant of RSUs (an award), which is compensation-related and not a market buy or sell—such grants do not necessarily indicate the insider is trading on a view of near-term share performance. The economic value realized will depend on the share price at vesting (Sept 15, 2026).
• Note the unusual ratio disclosed in the footnote: each RSU/ADS is said to represent the right to 80,000 ordinary shares; check company filings or investor relations for clarification of ADR/ADS ratios if you need to understand the underlying ordinary-share exposure.